Exco InTouch Joins C-Path ePRO Consortium
News May 21, 2013
Exco InTouch has announced that it has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, a programme run by the Critical Path Institute (C-Path), which strives to enhance the quality of patient reported outcomes (PRO) in the evaluation of new pharmaceuticals.
The ePRO Consortium is committed to improving the quality, practicality and acceptability of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment.
As PRO endpoints have become increasingly common in studies for evaluating patients’ perspectives of a particular drug, the requirement for better measures of patients’ experiences has become even more critical.
Exco InTouch will work closely with other Consortium members from a number of industry-leading providers of innovative electronic data collection technologies, to develop guidelines for the adaptation of PRO measures to the appropriate ePRO solutions.
The ePRO Consortium will generate measurement equivalence data, develop specification documents and data standards, and produce methodological guidance on measurement issues related to ePRO applications.
The association will also work closely with C-Path’s PRO Consortium, a group of 25 pharmaceutical companies working to develop novel PRO measures, with the goal of making these new measures available for electronic data capture formats.
The aim of the programme is to enhance public health by optimizing the value of PRO data in medical product evaluation and clinical decision making.
“Exco InTouch is delighted to join the ePRO Consortium to help advance the science of electronic data capture and create standardized guidelines to ensure all data collated electronically in clinical trials is valid and reliable,” comments Tim Davis, CEO of Exco InTouch.
Davis continued, “The Consortium provides a neutral and collaborative environment for the industry to work together to develop and advocate consistent approaches for drug development.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE